New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 17, 2014
08:08 EDTVRXValeant receives FDA clearance for Victus Femtosecond Laser Platform
Valeant Pharmaceuticals announced that its wholly owned subsidiary, Bausch + Lomb has received 510(k) clearance from the FDA for the Victus Femtosecond Laser Platform for laser-assisted lens fragmentation* during cataract surgery. The fragmentation procedure, which follows a capsulotomy, uses the femtosecond laser to split the cataractous lens into sections. This is followed by phacoemulsification for cataract removal. The Victus platform offers a number of different lens fragmentation patterns depending on the cataract grade and user preference.
News For VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 27, 2015
06:19 EDTVRXPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
09:18 EDTVRXValeant and Progenics' Relistor eceives positive opinion from EMA
Valeant (VRX) and Progenics (PGNX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for Relistor Subcutaneous Injection for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for Relistor, to 11 years from the date of approval.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use